Hansoh Pharmaceutical Group Co Ltd (3692)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 20 Oct 2026
Key indicators
| Last close | HKD 34.38 |
|---|---|
| 52-week range | 27.66 – 43.59 |
| Return, 1 month / 3 months | +0.9% / +6.4% |
| Return, 1 year / 3 years | −5.8% / +263.9% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 41.4% |
| Worst drawdown (1 year) | -34.1% |
| Average daily value traded | 369.57M HKD |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hansoh Pharmaceutical Group develops, manufactures and markets medicines, with a focus on oncology, anti-infective, diabetes and central nervous system treatments. The company supplies both generic and innovative drugs to hospitals and patients, mainly in China, and is based in Lianyungang in Jiangsu province. Its work spans research and development through to production and commercial distribution of pharmaceutical products for the Chinese healthcare market.
On this site Hansoh Pharmaceutical Group Co Ltd appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 3692, with prices in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hansoh Pharmaceutical Group Co Ltd (3692) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 34.38 on 20 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 403 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 5.8% and over the last three months it rose 6.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 0.4% | ||
| From 52-week high | -19.6% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.4% | ||
| 6-month return | -12.3% | ||
| 12-month return, skipping the last month | -6.6% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.1% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 369.57M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 35 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.9% |
|---|---|
| 1 month | +0.9% |
| 3 months | +6.4% |
| 6 months | −12.3% |
| 1 year | −5.8% |
| 3 years | +263.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 33.66 / 34.23 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Sep 2026 | HKD 0.2850 |
| 3 Jul 2026 | HKD 0.2000 |
| 22 Sep 2025 | HKD 0.2316 |
| 3 Jul 2025 | HKD 0.1353 |
| 20 Sep 2024 | HKD 0.2010 |
| 19 Jun 2024 | HKD 0.1422 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.